Pliant Therapeutics, Inc.
$1.29
▲
2.27%
2026-04-21 08:52:00
pliantrx.com
NMS: PLRX
Explore Pliant Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$79.87 M
Current Price
$1.29
52W High / Low
$1.95 / $1.09
Stock P/E
—
Book Value
$2.95
Dividend Yield
—
ROCE
-74.87%
ROE
-61.55%
Face Value
—
EPS
$-2.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
49
Beta
1.25
Debt / Equity
16.06
Current Ratio
12
Quick Ratio
12
Forward P/E
-1.05
Price / Sales
—
Enterprise Value
$-82.59 M
EV / EBITDA
0.56
EV / Revenue
—
Rating
None
Target Price
$2.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
| 2. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 3. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 4. | Longeveron Inc. | $1.04 | — | $25.59 M | — | -377.18% | -1.65% | $1.83 / $0.47 | $0.25 |
| 5. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 6. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
| 7. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -23.58 M | -28.27 M | -45.59 M | -58.94 M | -53.32 M | — |
| Net Profit | -23.58 M | -26.3 M | -43.3 M | -56.17 M | -49.73 M | — |
| EPS in Rs | -0.38 | -0.42 | -0.7 | -0.91 | -0.8 | -0.95 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 1.58 M | 9.69 M |
| Operating Profit | -156.37 M | -228.37 M | -184.15 M | -127.2 M |
| Net Profit | -149.34 M | -210.3 M | -161.34 M | -123.32 M |
| EPS in Rs | -2.41 | -3.4 | -2.61 | -1.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 225.23 M | 396.95 M | 512.15 M | 350.61 M |
| Total Liabilities | 44.02 M | 92.87 M | 38.58 M | 37.27 M |
| Equity | 181.21 M | 304.08 M | 473.58 M | 313.34 M |
| Current Assets | 196.45 M | 362.26 M | 505.5 M | 340.31 M |
| Current Liabilities | 16.36 M | 33.22 M | 28.52 M | 23.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -128.34 M | -155.5 M | -116.36 M | -94.63 M |
| Investing CF | 134.29 M | 140.34 M | -127.01 M | -150.2 M |
| Financing CF | -31.7 M | 23.12 M | 274.4 M | 226.85 M |
| Free CF | -128.71 M | -159.35 M | -117.28 M | -96.39 M |
| Capex | -0.37 M | -3.85 M | -0.92 M | -1.76 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -83.69% | — | — |
| Earnings Growth % | -30.35% | -30.83% | — | — |
| Profit Margin % | — | -10211.14% | -1273.32% | — |
| Operating Margin % | — | -11654.75% | -1313.37% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -10014.43% | -1246.33% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.